Informations générales (source: ClinicalTrials.gov)
Modulation of Anti-tumor T Cell Responses in Cancer Patients Treated by Concomitant Radiochemotherapy (i-RTCT)
Interventional
N/A
Centre Hospitalier Universitaire de Besancon (Voir sur ClinicalTrials)
mai 2017
novembre 2026
05 avril 2025
The aim of this study is to evaluate modulation of anti-tumor T cell responses in cancer
patients treated by concomitant radiochemotherapy (i-RTCT)
Etablissements
| Les établissements hors Île-de-France dont les données sont issues de ClinicalTrials.gov Origine et niveau de fiabilité des données | |||||
|---|---|---|---|---|---|
| Centre Georges François LECLERC - 21000 - Dijon - France | Etienne MARTIN, Dr | Contact (sur clinicalTrials) | |||
| CHU de Besançon - 25000 - Besançon - France | Sophie Depierre | Contact (sur clinicalTrials) | |||
| Hôpital Nord Franche-Comté - Montbéliard - France | SUN, Dr | Contact (sur clinicalTrials) | |||
| Institut Jean Godinot - Reims - France | Stéphanie SERVAGI VERNAT, Dr | Contact (sur clinicalTrials) | |||
Critères
Tous
Inclusion Criteria:
- Histologically confirmed NSCLC (Non Small Cell Lung Cancer) or SCLC (small cell lung
cancer) OR histologically confirmed Head and neck cancer
- Patient candidate to a first-line concomitant radiochemotherapy
- Written informed consent
- Histologically confirmed NSCLC (Non Small Cell Lung Cancer) or SCLC (small cell lung
cancer) OR histologically confirmed Head and neck cancer
- Patient candidate to a first-line concomitant radiochemotherapy
- Written informed consent
- Sequential radiochemotherapy, exclusive radiotherapy, or stereotactic radiotherapy
- History of adjuvant radiochemotherapy for cancer treatment
- Patients under immunotherapy, chemotherapy or other immunosuppressive drugs
(prednisone or prednisolone ≤ 10 mg/day is allowed)
- HIV, hepatitis C or B virus
- Patients with any medical or psychiatric condition or disease,
- Patients under guardianship, curatorship or under the protection of justice.